Merck & Co., Inc. — Director's Dealing 2023

Jun 30, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Merck & Co., Inc. (MRK)
CIK: 0000310158
Period of Report: 2022-12-02

Reporting Person: Romanelli Joseph (President, Human Health Int?l)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-12-02	Common Stock	P	59	$109.67	Acquired	59	Indirect
2022-12-05	Common Stock	P	107	$109.54	Acquired	20391.325	Direct
2022-12-06	Common Stock	P	30	$109.39	Acquired	20421.325	Direct
2022-12-13	Common Stock	P	56	$110.96	Acquired	20477.325	Direct
2022-12-19	Common Stock	P	7	$109.04	Acquired	20484.325	Direct
2023-02-21	Common Stock	P	11	$109.20	Acquired	20495.325	Direct
2023-03-20	Common Stock	P	136	$105.47	Acquired	20631.325	Direct
2023-03-24	Common Stock	S	35	$104.65	Disposed	20596.325	Direct
2023-04-26	Common Stock	P	3	$113.68	Acquired	20599.325	Direct

Footnotes

F1: None of the purchases or sales reported herein were directed by the reporting person, but were executed by a brokerage firm for the benefit of the reporting person's managed account, without the reporting person's knowledge. One of the reported transactions resulted in a short swing profit under Section 16(b) of the Securities Exchange Act of 1934, as amended ("Section 16(b)"), and the reporting person has disgorged $374.01 to the Issuer, which amount represents all profits related to these transactions in accordance with Section 16(b).